Year archive

Qyuns Therapeutics Co., Ltd. — 2026 filings

All 44 regulatory filings released by Qyuns Therapeutics Co., Ltd. (2509) in 2026, sourced directly from the official regulator.

44 Filings

2026 Period

2026 filings (44)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT MILESTONE PAYMENT RECEIVED FROM ROCHE FOR THE FIRST PARTICIPANT DOSED IN PHASE I CLINICAL TRIAL OF QX031N Regulatory Filings	2026-05-27	English
Next Day Disclosure Return Transaction in Own Shares	2026-05-27	English
VOLUNTARY ANNOUNCEMENT APPROVALS OF MARKETING AUTHORISATION APPLICATION AND SUPPLEMENTAL APPLICATION FOR QX001S (USTEKINUMAB INJECTION) FOR USE IN CROHN'S DISEASE Regulatory Filings	2026-05-21	English
Documents on Display Governance Information	2026-05-08	English
NOTICE OF 2025 ANNUAL GENERAL MEETING AGM Information	2026-05-08	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 29, 2026 AGM Information	2026-05-08	English
CIRCULAR FOR ANNUAL GENERAL MEETING AGM Information	2026-05-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 Regulatory Filings	2026-05-07	English
DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS Regulatory Filings	2026-04-29	English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Environmental & Social Information	2026-04-27	English
2025 ANNUAL REPORT Annual Report FY 2025	2026-04-27	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026 Regulatory Filings	2026-04-09	English
Terms of Reference of the Nomination Committee Governance Information	2026-03-27	English
Terms of Reference of the Remuneration and Appraisal Committee Governance Information	2026-03-27	English
Terms of Reference of the Audit Committee Governance Information	2026-03-27	English
Terms of Reference of the Strategy and Development Committee Governance Information	2026-03-27	English
(1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025; (2) PROPOSED CHANGE IN USE OF PROCEEDS; (3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION, RULES OF PROCEDURES FOR THE GENERA Earnings Release FY 2025	2026-03-27	English
DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT Regulatory Filings	2026-03-23	English
NOTICE OF BOARD MEETING Report Publication Announcement	2026-03-17	English
VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF CRUSEKITUG (QX002N) FOR TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2026-03-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026 Transaction in Own Shares	2026-03-05	English
Next Day Disclosure Return Transaction in Own Shares	2026-02-06	English
VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE UNDER THE REPURCHASE MANDATE Transaction in Own Shares	2026-02-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026 Transaction in Own Shares	2026-02-05	English
Next Day Disclosure Return Transaction in Own Shares	2026-02-04	English
Next Day Disclosure Return Transaction in Own Shares	2026-02-03	English
Next Day Disclosure Return Transaction in Own Shares	2026-02-02	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-30	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-29	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-27	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-26	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-21	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-20	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-19	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-16	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-15	English
VOLUNTARY ANNOUNCEMENT QX030N/CLD-423 ACHIEVED FIRST SUBJECTS DOSING IN PHASE I CLINICAL TRIAL CALDERA THERAPEUTICS SECURED CUMULATIVE FUNDING OF US$112.5 MILLION Regulatory Filings	2026-01-14	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-14	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-13	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-12	English
VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE UNDER THE REPURCHASE MANDATE Transaction in Own Shares	2026-01-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025 Transaction in Own Shares	2026-01-07	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-06	English
Next Day Disclosure Return Transaction in Own Shares	2026-01-02	English